Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
Yes, glutathione is found in foods such as fruits, vegetables, and meats
(previous blog post) One of the main perks with Semaglutide use at RMC is the decrease in food cravings and decreased appetite
Sandoval DA, D'Alessio DA
Na forma de suplemento, est disponvel em cpsula, lquido ou at mesmo injetvel
